[Trastuzumab (herceptin) for the medical treatment of breast cancer]. / Trastuzumab (herceptine) dans le traitement medical des cancers du sein.
Tunis Med
; 90(1): 6-12, 2012 Jan.
Article
em Fr
| MEDLINE
| ID: mdl-22311450
ABSTRACT
BACKGROUND:
Trastuzumab is humanized monoclonal antibody targeting her 2 neu receptor, overexpressed in 20% of breast cancers and part of the complex of Epidermal Growth Factor Receptor.AIM:
To review new advances in the knowledge of the practical use of "trastuzumab (Herceptin ®)" in breast cancer.METHODS:
Review of literature using medical data bases (Medline, Science direct) with the following key words breast cancer, targeted therapy, HER2 neu, transtuzumab/herceptineRESULTS:
Trastuzumab represent an important advance in breast cancer treatment with an improvement of median survival in metastatic setting and overall and disease-free survival in adjuvant setting in association with chemotherapy. Herceptin remain well tolerated with a low and rare risk of cardiac failure.CONCLUSION:
Trastuzumab is a new therapeutic tool very interesting to ameliorate prognosis of breast cancer.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Anticorpos Monoclonais Humanizados
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Female
/
Humans
Idioma:
Fr
Revista:
Tunis Med
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Tunísia